Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study

Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study

Abstract Background Sodium–glucose co-transporter 2 (SGLT2) inhibitors offer cardiovascular benefits in patients with heart failure, yet their direct effects on myocardial fibrosis—particularly in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D)—remain underexplored....

Full description

Saved in:
Bibliographic Details
Main Authors: Arif Albulushi, Kimia M. Askari, Ammar M. Al-Abedi, Malak A. Al-Kulaibi, Murtadha S. Hasan, Zahra Hosseini, Mezon T. Al-Rahman, Desmond B. Tanoh, Amjad S. Hasan, Yaseen Al-Helli, Ahmed Basouni
Format: Article
Language:English
Published: BMC 2025-07-01
Series:European Journal of Medical Research
Subjects:
HFpEF
Myocardial fibrosis
Dapagliflozin
SGLT2 inhibitors
Type 2 diabetes
Cardiac MRI
Online Access:https://doi.org/10.1186/s40001-025-02834-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40001-025-02834-7

Similar Items